Abstract
Bleeding from gastroesophageal varices (GEV) represents a potentially lethal complication of liver cirrhosis. Currently gastroscopy is the milestone as a screening test for varices and it is routinely offered once the diagnosis of cirrhosis is confirmed; however, non-invasive elastography techniques offer valuable alternatives and may help to discriminate patients at high risk of developing GEVs and first episode of bleeding from low-risk subjects.
Non-selective beta-blockers (NSBBs) and terlipressin represent the most commonly used pharmacological agents for prevention and management of acute bleeding, respectively. However, novel evidence suggest beneficial effects with the use of other molecules such as carvedilol or simvastatin.
Endoscopic band ligation is the most effective endoscopic treatment in the setting of either acute bleeding and primary/secondary prevention and it has nearly completely replaced sclerotherapy in the clinical practice.
Aim of this chapter is to provide an overview on recent improvements and latest developments concerning the pharmacological and endoscopic treatment of esophageal varices, particularly based on the most robust evidence-based findings.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767–77.
Kovalak M, Lake J, Mattek N, et al. Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database. Gastrointest Endosc. 2007;65:82–8.
Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38:266–72.
Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61.
The North Italian Endoscopic Club for the Study, Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983–9.
Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362:823–32.
Hernández-Gea V, Berbel C, Baiges A, García-Pagán JC. Acute variceal bleeding: risk stratification and management (including TIPS). Hepatol Int. 2018;12(Suppl 1):81–90.
Schiff ER, Maddrey WC, Reddy KR. Schiff’s diseases of the liver. 12th ed. Hoboken, NJ: Wiley-Blackwell; 2017. p. 304–8.
Beppu K, Inokuchi K, Koyanagi N, Nakayama S, Sakata H, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc. 1981;27:213–8.
Roccarina D, Rosselli M, Genesca J, Tsochatzis EA. Elastography methods for the non-invasive assessment of portal hypertension. Expert Rev Gastroenterol Hepatol. 2018;12(2):155–64.
Karatzas A, Konstantakis C, Aggeletopoulou I, Kalogeropoulou C, Thomopoulos K, Triantos C. Νon-invasive screening for esophageal varices in patients with liver cirrhosis. Ann Gastroenterol. 2018;31(3):305–14.
Gomez-Moreno AZ, Pineda-Tenor D, Jimenez-Sousa MA, Sánchez-Ruano JJ, Artaza-Varasa T, Saura-Montalban J, Ryan P, Resino S. Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: a retrospective study. PLoS One. 2017;12(9):e0184404.
Vizzutti F, Arena U, Rega L, Pinzani M. Non-invasive diagnosis of portal hypertension in cirrhotic patients. Gastroenterol Clin Biol. 2008;32:80–7.
Mazur R, Celmer M, Silicki J, Hołownia D, Pozowski P, Międzybrodzki K. Clinical applications of spleen ultrasound elastography - a review. J Ultrason. 2018;18(72):37–41.
Sharma P, Kirnake V, Tyagi P, Bansal N, Singla V, et al. Spleen stiffness in patients with cirrhosis in predicting esophageal varices. Am J Gastroenterol. 2013;108:1101–7.
de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52.
Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M, Blasco H, Procopet B, Tsochatzis E, Westbrook RH, Bosch J, Berzigotti A, Abraldes JG, Genescà J. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology. 2017;66(6):1980–8.
Jangouk P, Turco L, De Oliveira A, et al. Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis. Liver Int. 2017;37(8):1177–83.
Abraldes JG, Bureau C, Stefanescu H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “anticipate” study. Hepatology. 2016;64:2173–84.
Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310–35.
Calés P, Oberti F, Payen JL, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis. Eur J Gastroenterol Hepatol. 1999;11:741–5.
Lebrec D, Poynard T, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med. 1981;305:1371–4.
Poynard T, Calès P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med. 1991;324:1532–8.
Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, Riggio O, Venditti M. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35(2):362–9.
Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58:911–21.
Mookerjee RP, Pavesi M, Thomsen KL, Mehta G, Macnaughtan J, Bendtsen F, Coenraad M, Sperl J, Gines P, Moreau R, Arroyo V, Jalan R. CANONIC Study Investigators of the EASL-CLIF Consortium. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016;64(3):574–82.
Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, Burroughs AK. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009;29(8):1189–93.
Sersté T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794–9.
Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680–1690.e1.
Bossen L, Krag A, Vilstrup H, et al. Non-selective β-blockers do not affect mortality in cirrhosis patients with ascites: post hoc analysis of three RCTs with 1198 patients. Hepatology. 2015; https://doi.org/10.1002/hep.28352.
Bhutta AQ, Garcia-Tsao G, Reddy KR, et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther. 2017;47(1):78–85.
Chirapongsathorn S, Valentin N, Alahdab F, et al. Nonselective β-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(8):1096–104.
Facciorusso A, Roy S, Livadas S, Fevrier-Paul A, Wekesa C, Kilic ID, Chaurasia AK, Sadeq M, Muscatiello N. Nonselective beta-blockers do not affect survival in cirrhotic patients with ascites. Dig Dis Sci. 2018;63(7):1737–46.
Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of betablockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61:967–9.
Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60(3):643–53.
Ge PS, Runyon BA. When should the β-blocker window in cirrhosis close? Gastroenterology. 2014;146(7):1597–9.
Garcia-Pagan JC, Navasa M, Bosch J, et al. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology. 1990;11:230–8.
Bureau C, Péron J-M, Alric JL, et al. ‘A La Carte’ treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology. 2002;36:1361–6.
Sinagra E, Perricone G, D’Amico M, et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014;39:557–68.
Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634–41.
Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009;50:825–33.
Facciorusso A, Chandar AK, Murad MH, Prokop LJ, Muscatiello N, Kamath PS, Singh S. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(2):94–102.
Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology. 2000;120:975–83.
Buonamico P, Sabba C, Garcia-Tsao G, et al. Octreotide blunts post-prandial splanchnic hyperemia in cirrhotic patients: a double-blind randomized echo-Doppler study. Hepatology. 1995;21:134–9.
Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis and portal hypertension. A double-blind hemodynamic investigation. Hepatology. 1995;22:106–11.
Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology. 2001;120:161–9.
Abraldes JG, Rodrıguez-Vilarrupla A, Graupera M, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol. 2007;46(6):1040–6.
Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651–8.
Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160–70.
Sarin SK, Nanda R, Sachdev G, Chari S, Anand BS, Broor SL. Intravariceal versus paravariceal sclerotherapy: a prospective, controlled, randomised trial. Gut. 1987;28:657–62.
Kapoor A, Dharel N, Sanyal AJ. Endoscopic diagnosis and therapy in gastroesophageal variceal bleeding. Gastrointest Endosc Clin N Am. 2015;25(3):491–507.
Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med. 1992;326:1527–32.
Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med. 1995;123:280–7.
Singh P, Pooran N, Indaram A, Bank S. Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: a meta-analysis. Am J Gastroenterol. 2002;97:623–9.
Tierney A, Toriz BE, Mian S, Brown KE. Interventions and outcomes of treatment of postbanding ulcer hemorrhage after endoscopic band ligation: a single-center case series. Gastrointest Endosc. 2013;77:136–40.
Cardenas A, Fernandez-Simon A, Escorcell A. Endoscopic band ligation and esophageal stents for acute variceal bleeding. Clin Liver Dis. 2014;18:793–808.
Sung JJ, Luo D, Wu JC, et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy. 2011;43:291–5.
Haddara S, Jacques J, Lecleire S, et al. A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy. 2016;48:1084–95.
Pittayanon R, Prueksapanich P, Rerknimitr R. The efficacy of Hemospray in patients with upper gastrointestinal bleeding from tumor. Endosc Int Open. 2016;4:E933–6.
Holster IL, Brullet E, Kuipers EJ, et al. Hemospray treatment is effective for lower gastrointestinal bleeding. Endoscopy. 2014;46:75–8.
Ibrahim M, El-Mikkawy A, Mostafa I, et al. Endoscopic treatment of acute variceal hemorrhage by using hemostatic powder TC-325: a prospective pilot study. Gastrointest Endosc. 2013;78:769–73.
Ibrahim M, El-Mikkawy A, Abdalla H, et al. Management of acute variceal bleeding using hemostatic powder. United European Gastroenterol J. 2015;3:277–83.
Holster IL, Poley JW, Kuipers EJ, et al. Controlling gastric variceal bleeding with endoscopically applied hemostatic powder (Hemospray™). J Hepatol. 2012;57:1397–8.
Stanley AJ, Smith LA, Morris AJ. Use of hemostatic powder (Hemospray) in the management of refractory gastric variceal hemorrhage. Endoscopy. 2013;45(Suppl 2):E86–7.
Ibrahim M, El-Mikkawy A, Abdel Hamid M, Abdalla H, Lemmers A, Mostafa I, Devière J. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial. Gut. 2019;68(5):844–53.
Bari K, Garcia-Tsao G. Treatment of portal hypertension. World J Gastroenterol. 2012;18(11):1166–75.
Gluud LL, Klingenberg S, Nikolova D, Gluud C. Banding ligation versus b-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol. 2007;102:2842–2848; quiz 2841, 2849.
Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis. 2008;28:3–25.
Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E, Cavallarin G, Bolognesi M, Donada C, Bellini B, Torboli P, Gatta A. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology. 2004;127:476–84.
Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during haemorrhage and blood volume restitution. Gastroenterology. 1986;90:1232–40.
Castañeda B, Morales J, Lionetti R, Moitinho E, Andreu V, Pérez-Del-Pulgar S, Pizcueta P, Rodés J, Bosch J. Effects of blood volume restitution following a portal hypertensive related bleeding in anesthetized cirrhotic rats. Hepatology. 2001;33:821–5.
Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, Planas R, Arroyo V, Navasa M. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131:1049–56.
García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens F, Vinel JP, Mössner J, Bosch J. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–9.
Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either b-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther. 2010;32:859–71.
Lo GH, Chen WC, Lin CK, Tsai WL, Chan HH, Chen TA, Yu HC, Hsu PI, Lai KH. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. Hepatology. 2008;48:580–7.
Gonzalez R, Zamora J, Gomez-Camarero J, Molinero LM, Bañares R, Albillos A. Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008;149:109–22.
Luca A, D’Amico G, La Galla R, Midiri M, Morabito A, Pagliaro L. TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology. 1999;212:411–21.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Self Study
Self Study
1.1 Questions
-
1.
Which statement is true?
-
(a)
Non-selective beta-blockers (NSBBs) are less effective than endoscopic variceal band ligation (EVBL) as primary prophylaxis of variceal bleeding.
-
(b)
NSBBs are usually prescribed in monotherapy as secondary prophylaxis of variceal bleeding.
-
(c)
NSBBs are as effective as EVBL in primary prophylaxis of variceal bleeding.
-
(d)
a, b.
-
(a)
-
2.
Which statement is true?
-
(a)
According to Baveno VI criteria, screening gastroscopy is indicated in all cirrhotic patients.
-
(b)
According to Baveno VI criteria, screening gastroscopy is not indicated in patients with a liver stiffness <20 kPa and with a platelet count >150,000.
-
(c)
According to Baveno VI criteria, screening gastroscopy is contraindicated in cirrhotic patients.
-
(d)
None of the above.
-
(a)
1.2 Answers
-
1.
Which statement is true?
-
(a)
NSBBs lead to similar results as EVBL in primary prophylaxis of variceal bleeding. In the case of small varices NSBBs are usually preferred as EVBL may appear challenging in this subset of patients.
-
(b)
Cornerstone of secondary prophylaxis of variceal bleeding is the association of NSBBs and EVBL.
-
(c)
Randomized controlled trials and meta-analyses showed that association of NSBBs and EVBL is not superior to NSBBs alone in primary prophylaxis of variceal bleeding-CORRECT.
-
(a)
-
2.
Which statement is true?
-
(b)
According to Baveno VI criteria gastroscopy is not indicated in patients with a liver stiffness <20 kPa and with a platelet count >150,000-CORRECT.
-
(b)
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Facciorusso, A., Buccino, R.V., Muscatiello, N. (2020). Endoscopic and Pharmacological Treatment of Esophageal Varices. In: Radu-Ionita, F., Pyrsopoulos, N., Jinga, M., Tintoiu, I., Sun, Z., Bontas, E. (eds) Liver Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-24432-3_55
Download citation
DOI: https://doi.org/10.1007/978-3-030-24432-3_55
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-24431-6
Online ISBN: 978-3-030-24432-3
eBook Packages: MedicineMedicine (R0)